These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7920467)

  • 1. Cross-reactive potential of rabbit antibodies raised against a cyclic peptide representing a chimeric V3 loop of HIV-1 gp120 studied by biosensor technique and ELISA.
    Richalet-Sécordel PM; Deslandres A; Plaué S; You B; Barré-Sinoussi F; Van Regenmortel MH
    FEMS Immunol Med Microbiol; 1994 Jun; 9(1):77-87. PubMed ID: 7920467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactivity of monoclonal antibodies to a chimeric V3 peptide of HIV-1 with peptide analogues studied by biosensor technology and ELISA.
    Richalet-Sécordel PM; Zeder-Lutz G; Plaue S; Sommermeyer-Leroux G; Van Regenmortel MH
    J Immunol Methods; 1994 Dec; 176(2):221-34. PubMed ID: 7983380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolates.
    Boudet F; Lasarte JJ; Sarobe P; Borras-Cuesta F; Theze J
    AIDS Res Hum Retroviruses; 1996 Dec; 12(18):1671-9. PubMed ID: 8959242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization.
    Cheingsong-Popov R; Lister S; Callow D; Kaleebu P; Beddows S; Weber J
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1379-86. PubMed ID: 7888191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
    Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
    Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 positive human sera.
    Gómez CE; López-Campistrous AE; Duarte CA
    J Virol Methods; 1998 Mar; 71(1):7-16. PubMed ID: 9628216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain.
    Jansson M; Wahren B; Albert J; Scarlatti G; Franzén L; Kataaha PK; Katabira E; Mubiro F; Wigzell H; Rossi P
    AIDS; 1994 Apr; 8(4):413-21. PubMed ID: 8011244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120.
    Baillou A; Brand D; Denis F; M'Boup S; Chout R; Goudeau A; Barin F
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1209-15. PubMed ID: 7511395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.
    Riley JP; Pestano GA; Hosford K; Francis C; Xie JM; Mugyenyi P; Kataaha P; Katongole-Mbidde E; Anokbonggo WW; Guyden J
    Arch Virol; 1995; 140(8):1393-404. PubMed ID: 7544970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
    Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiepitope polypeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop.
    Duarte CA; Montero M; Seralena A; Valdés R; Jiménez V; Benítez J; Narciandi E; Madrazo J; Padrón G; Sánchez G
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):235-43. PubMed ID: 7517147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T; Kurth R; Norley S
    J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
    Ota A; Tanaka-Taya K; Ueda S
    Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.
    Schiappacassi M; Buratti E; D'Agaro P; Ciani L; Scodeller ES; Tisminetzky SG; Baralle FE
    J Virol Methods; 1997 Jan; 63(1-2):121-7. PubMed ID: 9015282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.